【摘要】 为进一步研究体外细胞实验筛选出的多药耐药逆转剂在体内的药效学，将其中Ｆｗ １３ 的ｔｅ４１ 用于人白血病Ｋ５６２／ＡＤＲ裸鼠移植瘤逆转试验。结果显示：对ＢＡＬＢ／ｃ－ｎｕ／ｎｕ 荷瘤鼠按每日、每只腹腔注射ＦＷ１３－ｔｅ４１０．２ｍ ｌ（相当于原生药０．２ｇ），连续注射１８ 日后，可将硫酸长春新碱（ＶＣＲ）对Ｋ５６２ ／ＡＤＲ的抑瘤率从１９．７９％ 提高到８６．５９％ ，与ＶＣＲ组比较有显著性差异（Ｐ＜ ０．０５）。提示该中药制剂对恶性肿瘤多药耐药具有较强的逆转作用，可望成为安全有效的化疗致敏剂。更多还原

【Abstract】 We have reported that three reverasal agents were sifted out from 32 Chinese galenicals through a series of cell culture tests. Among them, Fw13 te 41 has the best effect of reverasal cancer multidrug resistance (MDR) in vitro. In this study, the reversal action of Fw13 te 41 in vivo was studied on the animal model of nude mice with human leukemia k 562 /ADR.Twenty SPF BALB/c nu/nu nude mice with xenograft tumor were randomly divided into the control group( n =6),VCR group 〔intraperitoneal (i.p) VCR 250μg/week, n =5〕,VCR+Fw13 te 41 group(i.p VCR 250μg/week+Fw13 te 41 0.2ml/day, equivalent to crude drug 10g/kg, n =5), and Fw13 te 41 group (i.p Fw13 te 41 0.2ml/day, equivalent to crude drug 10g/kg, n =4). After 18 days, the rate of tumor inhibition(RTI) of VCR group was 19.79%, but the RTI of VCR+ Fw13 te 41 group was as high as 86.95% ( P <0.05). There results elemonstrate that the Chinese medicine Fw13 te 41 has an evident reversal action of malignancy MDR in vitro and in vivo.更多还原